Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.

Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration.

The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1.

Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications.

Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.